Top Botox Brands for a Youthful Glow

Botox has become a popular cosmetic procedure for reducing the appearance of wrinkles and fine lines, giving individuals a more youthful and refreshed look. As demand for such treatments has grown, so too has the variety of brands offering botulinum toxin injections. Some of the most reputable and widely recognized brands in the market include Allergan's Botox, Dysport, Xeomin, and Jeuveau. Each brand has its unique formulation and characteristics, catering to different patient preferences and needs. Interested in learning how these brands compare and which might be the best option for you? Read on to explore the specifics of each brand and determine which aligns with your cosmetic goals.

Illustration of botox

Best brands of botox in 2025

Allergan

Allergan, now part of AbbVie, is a leading producer of Botox, with its BOTOX® solution dominating the global botulinum toxin A market. In 2022, the global botulinum toxin A market was valued at nearly $6.6 billion, and Allergan's Botox accounted for a significant portion of this, with annual sales of nearly $4 billion in 2019. The company holds over half of the overall market value, along with other major players like Galderma and Merz Aesthetics. Botox is widely used for treating glabellar frown lines, periorbital lines, and forehead lines, among other applications. The market is expected to grow at a CAGR of 6.5% to reach nearly $10.2 billion by 2029.

Dysport

Dysport, produced by Ipsen, is a leading botulinum toxin type A product, widely recognized for its efficacy in reducing facial wrinkles and fine lines. It dominates a significant portion of the global botulinum toxin market, with Ipsen holding a 24% market share in 2021. Dysport is commercially available in over 85 countries and is known for its ability to diffuse slightly from the injection site, often requiring fewer injection points. The product is particularly popular for treating frown lines, forehead lines, and crow's feet, with results typically lasting several months. Its global presence and robust R&D efforts have solidified Ipsen's position as a major player in the botulinum toxin market. For more information on Dysport, please visit the Skin Surgery Center's website.

Xeomin

Xeomin, produced by Merz Pharmaceuticals, is a highly effective botulinum toxin A product, approved by the US FDA for treating cervical dystonia, blepharospasm, and moderate to severe frown lines. It is notable for being the first botulinum toxin that does not require refrigeration, and it contains only the active ingredient without additional proteins, potentially reducing the risk of antibody formation. Xeomin's effects occur within one week and last from three to six months, comparable to Botox. It has been used to treat over 84,000 people worldwide and is available in 50-unit and 100-unit vials. According to market projections, Xeomin is expected to maintain a significant market share, with its usage predicted to be stable or slightly increasing in the coming years. For more information about Xeomin wrinkle treatment, visit their website.

Jeuveau

Jeuveau, produced by Evolus, has emerged as a significant player in the cosmetic neurotoxin market, showcasing impressive growth with a 76% increase in sales in 2021, reaching $99.7 million, and a 36% year-over-year growth in recent periods. The brand has captured around 11-13% of the U.S. neurotoxin market share, positioning itself as a competitive alternative to Botox, which holds a 70% market share. Jeuveau's success is attributed to its targeted marketing strategies, particularly its focus on millennials and the medical spa sector, as well as its co-branded initiatives. The product is also noted for being 20-25% less expensive than Botox. With ongoing expansion, including a European launch and plans for an "extra strength" version, Jeuveau continues to gain traction in the aesthetics market. For more details, visit Evolus' official website.

Nabota

Nabota, developed by Daewoong Pharmaceutical, is a high-purity botulinum toxin type A product that has gained significant traction globally. Since its launch, Nabota has achieved an 11% market share in the U.S. beauty toxin market and recorded an annual growth rate of about 50%. It was the first Asian botulinum toxin product to receive FDA approval in 2019 and is marketed in the U.S. under the name Jeuveau. Nabota has obtained permission from 67 global countries and has partnerships in over 80 countries. The product is known for its rapid onset of action, long-lasting effects, and competitive pricing, making it a competitive alternative to established brands. Learn more about the features and advantages of Nabota.

Revanesse Versa

Revanesse Versa, developed by Prollenium Medical Technologies, is a highly regarded dermal filler for correcting moderate to severe facial wrinkles and folds, such as nasolabial folds. It has undergone rigorous FDA evaluation, ensuring its safety and efficacy for cosmetic use. Clinical studies have shown that Revanesse Versa provides smooth and natural-looking results, with high patient satisfaction rates comparable to other leading fillers like Restylane and Juvederm. For instance, studies have demonstrated that Revanesse Versa is non-inferior in terms of safety and effectiveness, with significant improvements in facial wrinkles and folds. Over 5.5 million syringes of Revanesse products have been sold worldwide, highlighting their popularity and reliability.

Myobloc

Myobloc, developed by Solstice Neurosciences, is a highly effective botulinum toxin type B product, clinically equivalent to Botox in treating cervical dystonia, as evidenced by a randomized, double-blind trial involving 111 patients. It is approved for use in the US, Canada, and Europe, and has been marketed by US WorldMeds, LLC since 2010. Myobloc has a proven track record of efficacy in pain relief and muscle relaxation, with common adverse events being mild to moderate and transient. The product is known as NeuroBloc in Europe and has been a significant player in the neurotoxin market, which is projected to grow at a CAGR of 8.6% from 2022 to 2031. Myobloc's unique formulation and non-interchangeable potency units ensure patient safety and distinguish it from other botulinum toxin products. For more information, visit the Myobloc official website.

Medytox

Medytox, a leading global biopharmaceutical company, is renowned for its innovative botulinum toxin products, including Innotox, a ready-to-use liquid botulinum toxin type A that smooths wrinkles by relaxing facial muscles. Founded in 2000, Medytox is the first approved botulinum toxin company in Korea and the world's fourth botulinum toxin manufacturing company. It is the only company worldwide that manufactures and provides three types of botulinum toxin products: Neuronox, Innotox, and Coretox. Medytox invests 20% of its sales in R&D, driving significant growth and innovation in the field. The company's products, such as Innotox, work faster than traditional Botox and require no mixing with saline, making them a favored choice among practitioners.

Botulax

Hugel's Botulax, known internationally as Letybo, is a leading botulinum toxin product that has achieved significant growth, with sales increasing by 41% year-over-year in the third quarter of 2024, driven by a 73% rise in overseas sales, particularly in the US and Asia-Pacific markets. The product has shown strong performance globally, contributing to Hugel's record net sales of KRW 105.1 billion and operating profit of KRW 53.4 billion in Q3 2024. Botulax is renowned for its hypoallergenic properties, minimal penetration, and precise effects, making it a preferred choice for treating facial wrinkles, muscle spasms, and hyperhidrosis. The company aims to secure a 10% share of the US toxin market within three years. With its high patient tolerance and long-lasting results of up to 6-9 months, Botulax stands out as a top contender in the global Botox market. For more information, visit their official website.

Azzalure

Azzalure, marketed by Galderma, is a leading brand for botulinum toxin type A, specifically developed for aesthetic use to treat moderate to severe glabellar lines. With over 40 million treatments in the EU and US, Azzalure has established a strong presence since its approval in several European countries, including France, the UK, Denmark, and Portugal, starting from 2009. The product has shown statistically significant improvements in clinical trials, with favorable safety and efficacy profiles. Galderma's partnership with Ipsen, which began in 2007, has been instrumental in its success, covering exclusive rights for aesthetic indications in various regions. Azzalure's effectiveness and patient satisfaction have been consistently high, contributing to Galderma's robust growth in the aesthetic dermatology sector.